New Delhi, May 25 (PTI) Continuing to fall for the second Also Read - Lupin gets USFDA nod for generic version of Tadalafil tablets

straight session today on earnings disappointment, shares of Also Read - Lupin gets 6 observations from USFDA for its Pithampur Unit-2

drug firm Lupin today ended the day over 7 per cent lower, Also Read - Lupin gets European Commission nod for myotonia treatment drug

wiping out Rs 5,003 crore from its market valuation in two


The stock tumbled 7.31 per cent to settle at Rs 1,137.95

on BSE. During the day, it dived 9.74 per cent to Rs 1,108 —

its 52-week low.

On NSE, shares of the company tanked 7.18 per cent to end

at Rs 1,140.20.

The stock was the worst performer among the Sensex and

Nifty components.

On the volume front, 5.11 lakh shares of the company were

traded on BSE and over 83 lakh shares changed hands on NSE

during the day.

Shares of Lupin had yesterday fallen by nearly 2 per cent

after results were announced, eroding Rs 5,003.09 crore from

its market valuation in two days.

“The company for Q4 FY17, posted results much below

expectations mainly on OPM and the net profit front,” said

Sarabjit Kour Nangra, VP Research Pharma, Angel Broking.

Lupin yesterday reported over 49 per cent dip in

consolidated net profit to Rs 380.21 crore for the fourth

quarter ended March, mainly on account of increase in expenses

and impact of foreign exchange fluctuation.

The company had posted a net profit of Rs 747.88 crore in

the corresponding quarter of previous fiscal.

However, consolidated total revenue from operations rose

to Rs 4,253.30 crore for the quarter under consideration as

against Rs 4,197.42 crore for the same period year ago. PTI

This is published unedited from the PTI feed.